- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02945462
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
The Safety and Efficacy of Using Bone Marrow-derived Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction in Diabetic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Four diabetic male patients ranging from 25-65 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests. Patients with any evidence of untreated hypogonadism, current urinary tract or bladder infection, clinically evident penile anatomical deformities, previous penile implant or penile vascular surgery, uncontrolled hypertension or hypotension, reported unstable Cardiovascular diseases, uncontrolled diabetes (HbA1c > 10%), or primary hyperlipidemia will be excluded. The investigators hypothesize that the intracavernous injection of stem cells will facilitate the recovery of erectile function resulting in satisfying clinical outcomes in patients.
This study was performed:
- To test the safety of autologous intracavernous bone marrow mesenchymal stem cells.
- To evaluate benefit for the patient concerning recovery of natural erection by performing detailed and specific diagnostic tests prior and post MSCs injection by a team from Jordan University Hospital and Cell Therapy Center in Jordan University.
- To study the feasibility, indication criteria and application modalities of Bone marrow mesenchymal stem cells for further wider study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult male patients ranging from 25 to 65 years.
- Type 1 or type 2 diabetic patients with a personal history of diabetes ≥ 5 years.
- History of chronic erectile dysfunction for at least six months.
- HbA1c ≤ 10%.
- Baseline International Index of Erectile Function (IIEF) score of < 26.
- Not interested or able to use Phosphodiesterase type 5 inhibitor (PDE-5i) drug therapy and willing to forgo these treatments for the first 6 month period following study treatment.
- Body mass index between 20 -30.
- Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.
Exclusion Criteria:
- Untreated hypogonadism or low serum total testosterone < 200 ng/dl.
- Current urinary tract or bladder infection.
- Any medical evidence of any infectious disease.
- Clinically evident penile anatomical deformities (e.g., Peyronie's disease) or history of priapism.
- Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.
- Current or previous malignancy.
- Patients with primary hyperlipidemia.
- Use of any non study treatment for erectile dysfunction within 4 weeks of study treatment.
- Lack of willingness to continue through 6 months after study treatment.
- Any previous penile implant or penile vascular surgery.
- Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or < 90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg).
- Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.
- Bleeding or clotting disorder, use of anticoagulant therapy.
- Lab values for complete blood count, prothrombin time/ partial thromboplastin time/international randomized ratio (PT/PTT/INR), Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine falling outside the normal lab values.
- Systemic autoimmune disorder.
- Significant active systemic or localized infection.
- Receiving immunosuppressant medications.
- HbA1c > 10%.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: autologous mesenchymal stem cells
Intervention: Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients |
Patients will be injected with autologous mesenchymal stem cells, intracavernously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: six months
|
Observation of any relevant adverse side effect resulting from the injection.
Assessing the safety of autologous Mesenchymal Stem Cells injection
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire
Time Frame: 18 months
|
Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Sexual Health Inventory for Men/ International Index for Erectile Function/ Erection Hardness Score (SHIM/IIEF/EHS) questionnaire. For every patient tests would be performed at baseline and repeated at 1,3, 6,12, and 18 months post-injection. |
18 months
|
Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.
Time Frame: 6 months
|
Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Dynamic Infusion Cavernosometry test at baseline and repeated at 6 months post injection.
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDUJCTC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
University of BaghdadCompletedSexual Dysfunction | Erectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Sexual Abstinence | Erectile Dysfunction With Diabetes Mellitus | Sexual Desire Disorder | Erectile Dysfunction Following Cryotherapy | Erectile Dysfunction... and other conditionsIraq
-
Cairo UniversityCompletedVasculogenic Erectile DysfunctionEgypt
-
InitiaTerminatedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionIsrael
-
InitiaCompletedVasculogenic Erectile DysfunctionCzech Republic, Lithuania, Netherlands, Palestinian Territories, Occupied
-
Rexahn Pharmaceuticals, Inc.CompletedErectile Dysfunction (ED)United States
-
SK Chemicals Co., Ltd.TerminatedMale Erectile Dysfunction
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
Clinical Trials on autologous mesenchymal stem cells
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); Food and Drug...Active, not recruiting
-
Mashhad University of Medical SciencesCompleted
-
University of JordanCompletedOsteoarthritis, Knee | Articular Cartilage Disorder of KneeJordan
-
Clínica Las Condes. LIT INNOVA CORFOUnknownSpinal Cord InjuryChile
-
Mayo ClinicCompletedAmyotrophic Lateral SclerosisUnited States
-
Karolinska InstitutetCompletedMultiple Sclerosis | Autologous Mesenchymal Stem CellsSweden
-
University of JordanCompletedMultiple SclerosisJordan
-
Antonio UccelliAzienda Ospedaliera Universitaria Integrata Verona; Ospedale San RaffaeleUnknown
-
Karolinska InstitutetCompleted